Cmax is out of the range [Study As­sess­ment]

posted by jag009  – NJ, 2018-08-02 17:56 (990 d 16:53 ago) – Posting: # 19128
Views: 2,958

Hi,

» We recently conducted a BE trial. It was a classical 2-period, 2-sequence study of a drug that consists of a combination of two active substances. Unfortunately, results one of analytes, a parent drug, fell sightly outside of the 80-125% range, below 80% for Cmax. CV was below 30% and post-hoc power was less than 80% for this analyte...

Sorry, there is no way for you to argue.
John

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 9 (0 registered, 9 guests [including 3 identified bots]).
Forum time: Monday 10:50 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5